Business
Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15th 2026 at 1:15 PM PST / 4:15 PM EST. in San Francisco, CA.
About this update from Jp Morgan Chase & Co.
[{"type":"text","content":"SHANGHAI and BOSTON, Jan. 11, 2026 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15th 2026 at 1:15 PM PST / 4:15 PM EST. in San Francisco, CA.","length":446,"tagName":"p"},{"type":"image","alt":"Argo Biopharma Logo","displaySize":"","headline":null,"caption":"Argo Biopharma Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":390,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/8b32f7813b5a5e274387f6ed4e989f75"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1BU74bK3.ERtEzo9pzOUHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/8b32f7813b5a5e274387f6ed4e989f75","width":390,"height":129}},"href":"https://mma.prnewswire.com/media/2858846/argo_biopharma_logo_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"About Argo Biopharma","length":20,"tagName":"p"},{"type":"text","content":"Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.","length":478,"tagName":"p"},{"type":"text","content":"For more information, visit www.argobiopharma.com.","length":50,"tagName":"p"},{"type":"image","alt":"Cision","displaySize":"","headline":null,"caption":"Cision","className":"","disableSlideshowImg":false,"size":{"original":{"width":12,"height":12,"url":"https://media.zenfs.com/en/prnewswire.com/43252764c5b9eac039a774465abcf24e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yM4aqp_64bCR1syVIbeOxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2O2g9MzY7Y2Y9d2VicA--/https://media.zenfs.com/en/prnewswire.com/43252764c5b9eac039a774465abcf24e","width":12,"height":12}}},{"type":"text","content":"View original content to download multimedia:...